Rhenman & Partners Asset Management AB Purchases 240,000 Shares of Kura Oncology, Inc. $KURA

Rhenman & Partners Asset Management AB increased its position in Kura Oncology, Inc. (NASDAQ:KURA) by 96.0% in the third quarter, HoldingsChannel reports. The firm owned 490,000 shares of the company’s stock after purchasing an additional 240,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Kura Oncology were worth $4,336,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kura Oncology by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after purchasing an additional 2,977 shares during the period. Strs Ohio purchased a new position in Kura Oncology during the first quarter valued at $143,000. Teacher Retirement System of Texas boosted its holdings in shares of Kura Oncology by 29.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 16,235 shares of the company’s stock valued at $94,000 after buying an additional 3,683 shares in the last quarter. Savant Capital LLC grew its position in shares of Kura Oncology by 74.1% in the 2nd quarter. Savant Capital LLC now owns 87,974 shares of the company’s stock worth $508,000 after buying an additional 37,450 shares during the period. Finally, Fox Run Management L.L.C. increased its stake in shares of Kura Oncology by 31.5% in the 2nd quarter. Fox Run Management L.L.C. now owns 31,546 shares of the company’s stock worth $182,000 after acquiring an additional 7,557 shares in the last quarter.

Insider Activity at Kura Oncology

In related news, insider Teresa Brophy Bair sold 11,208 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $94,819.68. Following the sale, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This trade represents a 4.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider owned 267,274 shares of the company’s stock, valued at $2,261,138.04. The trade was a 2.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 59,794 shares of company stock valued at $537,176 over the last three months. 6.40% of the stock is owned by insiders.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $8.96 on Friday. The firm has a market cap of $779.70 million, a P/E ratio of -2.82 and a beta of 0.22. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $12.49. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $8.75 and a 200 day moving average of $9.41.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The business had revenue of $17.34 million for the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 91.62%. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KURA. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Wall Street Zen downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Wedbush reduced their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.71.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.